Pulmonary Nodule Management Guidelines

Initial Evaluation and Risk Stratification

The American College of Chest Physicians recommends that the management of pulmonary nodules be determined by nodule size, composition, patient risk factors for lung cancer, and probability of malignancy, with a critical threshold of 8 mm for solid nodules 1, 2
For solid indeterminate nodules >8 mm, the American College of Chest Physicians suggests estimating the pretest probability of malignancy using clinical judgment and/or validated prediction models, such as the Brock model, considering key risk factors including smoking history, age ≥65 years, family history of lung cancer, and nodule characteristics 1, 2, 4
The American College of Chest Physicians recommends obtaining prior imaging studies to determine if the nodule has been stable for ≥2 years, indicating benignity for solid nodules and requiring no further workup 3, 4

For solid nodules ≤4 mm with no risk factors, the American College of Chest Physicians recommends no follow-up, while those with one or more risk factors should have a single follow-up low-dose CT at 12 months 1, 2, 5
For solid nodules >4-6 mm with no risk factors, the American College of Chest Physicians suggests follow-up CT at 12 months, while those with one or more risk factors should have follow-up CT at 6-12 months, then again at 18-24 months if unchanged 1, 2, 5
For solid nodules >8 mm, the American College of Chest Physicians recommends referral to pulmonology or a multidisciplinary team, with management depending on the estimated probability of malignancy 1, 2, 4, 6

The American College of Chest Physicians recommends using low-dose, non-contrast CT technique, thin sections (≤1.5 mm, typically 1.0 mm), and multiplanar reconstructions for surveillance imaging 1, 2, 5, 6

For patients with life-limiting comorbidities, the American College of Chest Physicians suggests limited duration or no follow-up, as a low-grade malignancy would be of little consequence 1, 5
For immunocompromised patients, individualized management is required, as infectious causes are more likely 5
For patients with known extrathoracic malignancy, oncology-directed surveillance is recommended rather than standard nodule guidelines 5, 6